Siglec1 has increased expression in CD14+ monocytes in MS patients, specifically those with the progressive disease form [79], and was shown to play a role of a promoter for neuroinflammation in EAE models of MS [80]. Here, SIGLEC1 is linked to myeloid sarcoma.